Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.3
-307.86%
60%
—
-98.98%
40%
—
5 Years
Score3.3
Net Growth-307.86%
Net Trend60%
Net Income Consistency—
Rev Growth-98.98%
Rev Trend40%
Revenue Consistency—
Mereo BioPharma Group PLC ADR fundamental performance
Across Mereo BioPharma Group PLC ADR's full reported history, from 2019 to 2025, revenue went from -£ 122K to £ 500K and net income went from -£ 44M to -£ 41M. Revenue increased in 57% of the years measured; net income in 57%.
Mereo BioPharma Group PLC ADR currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 0.30 | — |
1 Year2025-08-12 | $ 1.66 | -81.75% |
5 Years2021-08-12 | $ 2.35 | -87.11% |
All Time2019-04-24 | $ 6.50 | -95.34% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-04-24 |
|---|---|---|---|---|
| Price | $ 0.30 | $ 1.66 | $ 2.35 | $ 6.50 |
| Return | — | -81.75% | -87.11% | -95.34% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | £ 500K | -£ 35M | £ 36M |
| 2025 | £ 500K | -£ 41M | £ 40M |
| 2024 | £ 0.00 | -£ 43M | £ 69M |
| 2023 | £ 10M | -£ 29M | £ 57M |
| 2022 | £ 1M | -£ 42M | £ 68M |
| 2021 | £ 49M | £ 17M | £ 127M |
| 2020 | £ 393K | -£ 209M | £ 32M |
| IPO2019 | -£ 122K | -£ 44M | £ 21M |
Explore beyond MREO
You're looking at Mereo BioPharma Group PLC ADR. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
